greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2018

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2018: revenue JPY 1,771 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2018 it reported revenue of JPY 1,771 billion ($16.0 billion at the year's average rate), up 2.2% on the year before. Its profit attributable to shareholders was JPY 187 billion, up 62.6%, and diluted earnings per share JPY 237.56.

Revenue
JPY 1,771 billion
+2.2% on the year
FY2017FY2018
Operating margin
13.7%
9.0% a year earlier
FY2017FY2018
Net income
JPY 187 billion
+62.6% on the year
FY2017FY2018
Diluted EPS
JPY 237.56
+62.4% on the year
FY2017FY2018

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2017Mar 2018
Revenue1,7321,771
Cost of sales559496
Research and development312325
Operating profit156242
Finance costs23.231.9
Profit before tax143217
Income tax27.830.5
Profit for the year116187
Profit attributable to shareholders115187
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2017Mar 2018
Diluted EPS146.26237.56
Basic EPS147.15239.35
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2017Mar 2018
Cash from operations261378
Purchase of property, plant and equipment61.767.0
Free cash flow200311
Cash from investing-656-93.3
Cash from financing290-326
Depreciation and amortisation171182
Buybacks23.118.8
Dividends paid142142
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2017Mar 2018
Funded by
Equity attributable to shareholders1,9491,997
Non-controlling interestsn/a20.0
Borrowings, as filedn/a986
Other liabilitiesn/a1,103
Total equity and liabilitiesn/a4,106
Owned
Property, plant and equipmentn/a537
Goodwilln/a1,029
Other intangible assetsn/a1,014
Cash and cash equivalents319295
Trade and other receivablesn/a420
Inventoriesn/a213
Other assetsn/a598
Total assetsn/a4,106
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2017Mar 2018
Operating margin9.0%13.7%
Net margin6.6%10.6%
Free cash flow margin11.5%17.6%
Return on year-end equity5.9%9.4%
Effective tax rate19.4%14.0%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2018, filed 24 June 2020: the filing. The figures are in yen as filed.